Open AccessOncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice
Author(s) -
Martin Faehling,
B. Schwenk,
Sebastian Kramberg,
R. Eckert,
AnnaLena Volckmar,
Albrecht Stenzinger,
Jörn Sträter
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.20857
Subject(s) - medicine , lung cancer , oncology , cancer research , population , environmental health
Oncogenic driver mutations activating EGFR , ALK , or BRAF in NSCLC predict sensitivity to specific tyrosine-kinase inhibitors (TKIs). We provide data on prevalence, treatment and survival of driver-mutation positive NSCLC in a predominantly Caucasian population in routine clinical practice.